Lack of revenue and earnings? It made tons of cash. More importantly, GSK has very robust late stage pipelines, better than the most big pharmas. The chart tells me it is oversold and it may have found the bottom when it hit $36 range. It shows it could hit $38.75, which is next major resistance. If it clears that resistance, it will hit $40+.